Amgen, the world’s largest biotechnology company, said today that its experimental drug for osteoporosis reduced the rate of fractures in a pivotal clinical trial of 7,800 women who took the drug or a placebo. The rate of side effects, including infections, were similar for patients on denosumab and the placebo, the company said. Thousand Oaks, CA-based Amgen (NASDAQ: [[ticker:AMGN]]) has about 1,000 employees in Seattle and Bothell. Analysts have predicted the new drug could exceed $2 billion in annual sales if approved by the FDA.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
